<DOC>
	<DOCNO>NCT00773344</DOCNO>
	<brief_summary>The primary purpose ( ) study determine high tolerate dose tanespimycin determine anti-tumor activity ( via objective response rate ) tanespimycin patient breast cancer previously respond Herceptin</brief_summary>
	<brief_title>Clinical Trial Combination Trastuzumab ( Herceptin ) Tanespimycin Patients With Solid Tumors Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age &gt; =18 year KPS performance status &gt; = 70 % For Phase 1 portion trial , patient must histologically confirm solid tumor malignancy . For Phase 2 portion trial , patient must metastatic breast cancer HER2 amplification FISH 3+ HER2 overexpression immunohistochemistry ( `` IHC '' ) Patients may either progressive disease within 3 month follow last dose adjuvant treatment trastuzumab OR progressive disease follow initial therapy metastatic disease trastuzumab ( trastuzumab may administer cytotoxic chemotherapy , hormonal therapy single agent . ) Patients receive trastuzumab single agent therapy ( without document progressive disease ) follow trastuzumab combination therapy remain eligible study time disease progression . Patients must measurable disease RECIST All Adverse Events prior chemotherapy , surgery , radiotherapy , must resolve NCI CTCAE ( v. 3.0 ) Grade &lt; = 2 ( except alopecia ) The following laboratory result , within 10 day KOS953 administration : Hemoglobin &gt; = 8.5 g/dL Absolute neutrophils count &gt; = 1.5 x 10*9* /L Platelet count &gt; = 75 x 10*9* /L Serum bilirubin &lt; = 2 x ULN AST ALT &lt; = 2 x ULN Serum creatinine &lt; = 2 x ULN Signed informed consent Documented hypersensitivity reaction CTCAE Grade &gt; = 3 prior therapy contain Cremophor ( patient receive Tanespimycin Injection ) Herceptin Pregnant breastfeed woman Known active CNS metastasis Except trastuzumab ( HerceptinÂ® ) administer 721 day prior first tanespimycin ( KOS953 ) administration , administration chemotherapy , biological , immunotherapy investigational agent ( therapeutic diagnostic ) within 14 day prior receipt study medication . Patients 6 week last dose nitrosourea Severe dyspnea rest cause complication advanced malignancy require supplementary oxygen therapy Congestive heart failure , leave ventricular ejection fraction ( LVEF ) less 50 % assess multigated radionuclide angiography scan echocardiography Any medical condition , Investigator 's opinion , would impose excessive risk patient Patients previous malignancy unless free recurrence least 5 year except cure basal cell carcinoma skin , carcinomainsitu either uterine cervix urinary bladder , Stage T1 T2 prostate cancer whose PSA &lt; 2 ng/mL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Solid Tumors ( dose escalation/Phase 1 )</keyword>
	<keyword>Breast Cancer ( recommend dose phase/Phase 2 )</keyword>
</DOC>